Published in Am J Pathol on November 01, 2005
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci (2011) 1.79
Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med (2015) 1.07
Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol (2010) 1.04
Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One (2011) 1.03
Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromolecular Med (2012) 1.00
Inhaled anesthetic potency in aged Alzheimer mice. Anesth Analg (2009) 0.91
Sleep and EEG features in genetic models of Down syndrome. Neurobiol Dis (2007) 0.90
Entorhinal cortical defects in Tg2576 mice are present as early as 2-4 months of age. Neurobiol Aging (2014) 0.85
The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag (2014) 0.84
Mammalian sleep genetics. Neurogenetics (2012) 0.80
Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease. Neuroscience (2015) 0.80
Amyloid-β induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila. J Neurosci Res (2016) 0.77
Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathology. Sci Rep (2016) 0.76
Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages. PLoS One (2015) 0.76
Cyclic intensive light exposure induces retinal lesions similar to age-related macular degeneration in APPswe/PS1 bigenic mice. BMC Neurosci (2012) 0.76
Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms (2016) 0.75
Sleep-wake disturbance in patients with brain tumors. Neuro Oncol (2016) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci (2001) 4.33
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Conditioned and unconditional components of post-shock freezing. Pavlov J Biol Sci (1981) 4.20
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep (2004) 2.88
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest (2003) 2.60
The homeostatic regulation of sleep need is under genetic control. J Neurosci (2001) 2.56
Senile dementia of the Alzheimer type. Ann Neurol (1983) 2.47
Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav (2002) 1.99
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol (1997) 1.95
Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health (1990) 1.84
Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet (1999) 1.74
An automated system for recording and analysis of sleep in mice. Sleep (2000) 1.32
Sleep, EEG and mental function changes in senile dementia of the Alzheimer's type. Neurobiol Aging (1982) 1.31
Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol (2003) 1.30
Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc (1982) 1.24
Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone (2004) 1.18
Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience (2005) 1.14
Scoring transitions to REM sleep in rats based on the EEG phenomena of pre-REM sleep: an improved analysis of sleep structure. Sleep (1994) 1.14
Modeling caregiver adaptation over time: the longitudinal impact of behavior problems. Psychol Aging (2000) 1.13
Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem (2002) 1.13
Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience (1991) 1.11
Sleep in Alzheimer's disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep (1995) 1.04
Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging (2002) 1.02
Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp Neurol (2001) 1.01
An immediate-shock freezing deficit with discrete cues: a possible role for unconditioned stimulus processing mechanisms. J Exp Psychol Anim Behav Process (2001) 1.01
Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res (2004) 0.96
Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol (1993) 0.91
The relations among caregiver stress, "sundowning" symptoms, and cognitive decline in Alzheimer's disease. J Am Geriatr Soc (1992) 0.87
Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res (2003) 0.86
Alzheimer plaques and cortical cholinergic innervation. Neuroscience (1986) 0.86
Sleep-wake architecture in mouse models for Down syndrome. Neurobiol Dis (2004) 0.85
EEG markers of early Alzheimer's disease in computer selected tonic REM sleep. Electroencephalogr Clin Neurophysiol (1992) 0.81
Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: a biological marker of Alzheimer's disease. Ann Neurol (1992) 0.80
Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease. J Neurol Sci (1990) 0.79
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron (2009) 5.22
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci (2007) 5.02
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Pathophysiology of sleep apnea. Physiol Rev (2010) 4.69
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell (2005) 4.25
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol (2005) 4.00
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem (2008) 3.56
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem (2005) 3.37
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (2010) 3.16
Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci (2011) 3.06
Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol (2006) 3.01
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83